FY26 Results Investor Briefing
Released
Released
Announcement PDF
FY26 Investor Briefing | Page 1
ASX Announcement
18 August 2026
FY26 Results Investor Briefing
Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial
results for the year ended 30 June 2026 and also provides commentary in respect of the business and
financial outlook.
The presentation material is attached to this announcement.
Investors are invited to join a live webcast and Q&A hosted by Brad O’Connor, CEO, Darren Watson, CFO
and Rachel Colite Executive Vice President, Clinical Trials on Tuesday 18th August 2026 at 12:00pm
Australian Eastern Daylight Savings Time.
Please register at: https://investors.cogstate.com/webinars/XyOWVy-cogstate-fy2026-financial-results
A video recording of the presentation will be available following the presentation at the Cogstate Investor Centre
homepage: https://investors.cogstate.com.
This announcement was authorised for release by a sub-committee of the Board of Cogstate.
For further information contact: investor@cogstate.com
FY26 Investor Briefing | Page 2
About Cogstate
Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance
the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide
rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support partners
in the delivery of electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper
assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services
for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting.
For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical
companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the
Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and
scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform
patients and save physician time. For more information, please visit www.cogstate.com.
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of
Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied
upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in
this announcement, nor any information made available to you is, or shall be relied upon as, a promise, representation,
warranty or guarantee, whether as to the past, present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”,
“intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position
and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided
in this announcement are based on assumptions and contingencies that are subject to change without notice and
involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its
directors and management. Forward-looking statements are provided as a general guide only and should not be
relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such
statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be
realised in the period for which the forward-looking statement may have been prepared or otherwise. For example,
Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period,
or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by factors that are
outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or
regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forward-
looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this announcement. The forward-looking statements are based on information available to Cogstate as
at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of
Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information,
whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.
Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-
looking statements.
© 2026 Cogstate Ltd. All rights reserved.
FY26 Full Year Results
18 August 2026
Brad O’Connor, CEO | Darren Watson, CFO | Rachel Colite, EVP Clinical Trials
2
2
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature
and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in
accordance with the requirements of the Corporations Act. This presentation may contain statements, opinions, projections,
forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may or may not
prove to be correct. None of Cogstate, its respective officers, employees, agents, advisers or any other person named in this
presentation makes any representation as to the accuracy or likelihood of fulfilment of any forward looking statements or any of the
assumptions upon which they are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or particular
needs of any recipient and is not financial product advice. Before making an investment decision, recipients of this presentation
should consider their own needs and situation and, if necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty,
representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation. Further,
none of Cogstate and its respective officers, employees, agents and advisers accept, to the extent permitted by law, responsibility
for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained in this presentation.
Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information contained herein.
3
3
A landmark year achieved through
diversification and expansion of offering.
Delivered record sales, revenue and profit,
while investing with discipline to support
the next phase of growth.
4
Investment Highlights
Record profitable
growth & visibility
Well-capitalised
balance sheet
Technology-driven
margin expansion
Sales inflection in a
growing market
Unique competitive
position
$60.9m revenue; 25%
EBIT margins.
Strong visibility to
future revenue growth.
Clear operating
leverage as we scale:
• EBIT Margin up to
30% in 2H26 on
higher revenue.
$34.8m net cash, no
debt.
Strong operational
cash flow for self-
funded growth.
Annual dividend and
active share buyback.
Strategic channel
partnerships expanding
market reach.
Material improvement
in growth trajectory as
CNS trial-starts
continue to grow.
Combining deep
neuroscience expertise
with scalable
technology to help
biopharma develop
brain health therapies
more efficiently and
with greater
confidence.
AI and automation
creating a step-change
opportunity to expand
margins and launch
new software-led
offerings.
1 2 3 4 5
All figures in US$ unless otherwise stated
5
Sales Contracts
$89.0m up 116%
Contracted Revenue
Over time: $118.5m
FY27: $48.3m, up 54%
Trial Starts
90 initiated (vs 35)
171 running (vs 110)
Growth
Cash $34.8M
No debt
Investment
Self-funded tech
Capital Allocation
Buyback & Dividend
Discipline
FY26 Scorecard – A Record Breaking Year
All figures in US$ and comparison is to previous corresponding period
Revenue $60.9m
Up 15%
Gross Profit $35.4m
58% GP margin via
2H26 margin of 62%
Profitability
PBT $16.1m
Up 16%
6
58%
51%
56%
61%
58%
24%
7%
16%
26%
26%
0
5
10
15
20
25
30
35
40
45
50
55
60
65
FY22 FY23 FY24 FY25 FY26
US$
Millions
Revenue & Profitability,
by Financial Year
Revenue Gross Profit Profit Before Tax
Profitable Growth at Scale
• Delivered sustained growth with
increasing profitability over time.
• FY26 demonstrates the operating
leverage in the model.
• 27% revenue growth 2H26 vs 1H26
• 2H26 revenue growth delivered
margin expansion:
• 2H26 Gross Profit margin 62%
• 2H26 EBITDA margin 35%
• Business scaled while continuing to
invest in product innovation, customer
growth and delivery capability.
6
7
• FY27 starts from a record base of committed revenue.
• Future growth still depends on in-period conversion of new
contracts, but the starting position is materially stronger.
• $48.3m FY27 revenue under contract at 30-Jun-2026, up
54% on last year
- Clinical Trials $46.1m, up 58% YTY (see table)
- Healthcare $2.3m, consistent with FY26.
Clinical Trials Healthcare
-
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
FY27 FY28 FY29 FY30 FY31+
US$
Millions
Clinical Trials Backlog Run-Off Comparison
30 June 2026 30 June 2025
FY27 $46.1m FY26 $29.2m
FY28 $29.1m FY27 $19.1m
FY29 $18.4m FY28 $10.8m
FY30 $5.4m FY29 $13.8m
FY31+ $8.1m FY30+ $3.4m
Total $107.1m Total $76.3m
Record Contracted Revenue Provides Forward Visibility
$118.5m, of which $48.3m expected to be recognised in FY27
7
8
Trial Starts are Increasing, Portfolio is Diversifying
FY26: 90 new trial starts (vs 35 FY25)
• 14% Alzheimer’s.
• 46% Mood, Sleep & Other Neurology.
• 33% Rare Diseases.
• 7% Cancer, Metabolic and Other Diseases.
Alzheimer’s
Mood, Sleep & Other
Neurological
Rare
Cancer Metabolic &
Other
0
5
10
15
20
25
30
35
40
45
50
55
1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26 2H26
Number
of
Trials
Number of New Trial Starts, per Half
• Record number of new trial starts.
• Project base is broader, deeper and more resilient.
• Higher active trial numbers support multi-year
revenue opportunity.
• Increasingly positioned as the incumbent endpoint
provider as programs progress.
• Scale provides significant opportunity for
automation and further margin growth.
8
9
Ongoing Trials by Phase and by Indication
Alzheimer’s
Mood, Sleep &
Other Neuro
Rare Disease
Cancer, Metabolic
& Other
Jun-26
Total
Jun-25
Total
Phase 3 9 16 15 2 42 25
Phase 2 12 31 29 6 78 45
Phase 1 6 10 9 1 26 23
Other 6 6 13 0 25 17
Total 33 63 66 9 171 110
• Record number of ongoing trials: 171, up 55%.
• Significant growth in mood, sleep & other neuro supports the expansion strategy.
• Central rating is a key feature of mood trials, enhancing the average value of those trials for Cogstate.
• 78 ongoing phase 2 trials (up 73%) presents significant growth opportunity for future phase 3 trials.
10
Revenue Performance of Clinical Trials is Accelerating
15
17
19
21
23
25
27
29
31
33
35
1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26 2H26
US$
Millions
2H26 Clinical Trials Revenue $32.7m
• 17% growth pcp and 27% growth compared to most
recent half-year
- Strong second half consistent with recent
years.
• License fee revenue 24% of 2H26 revenue
- 23% in 1H26
- 31% in 2H25
- 19% in 1H25
• Central rating revenue significant, but has different
yield profile to license fee revenue
- Slower yield over first two quarters, then
accelerates.
11
What’s driving increased sales opportunities?
Multiple drivers expanding Cogstate’s growth
• Expanding beyond neurology (brain
health) and aggressively into
psychiatry (mental health).
• Leadership position in orexin
programs, with Cogstate assessments
serving as key endpoints in most trials.
• Growing sponsor investment in sleep
highlighted by Lilly’s $7.8bn acquisition
of Centessa.
• Continued momentum in rare disease
programs, particularly among biotech
sponsors.
Indication expansion
• Shift toward decentralised and remote
trial execution is expanding demand for
Cogstate's solutions.
• Global Central Rating capability
delivered by 400+ neuropsychologists
spanning 50+ languages.
• Significant capacity to scale through
additional 3,200+ pre-screened
clinicians in network.
Expansion of offering
• Growing CNS clinical trial activity is
expanding the addressable market,
including increased investment in:
• Orexin programs in sleep
• Psychedelics and Incretin
programs in mood disorders
• Gene therapy and genetic
medicines in rare neuro
• Channel partnerships are broadening
our market reach, including Medidata
and other partnerships, that are
generating incremental opportunities.
• Increasing adoption by leading
biopharma is strengthening Cogstate’s
global footprint.
Market conditions
11
12
Partnerships Support Repeatable Growth
• Strategic partnerships are embedding
Cogstate solutions within leading clinical
trial platforms.
• These relationships broaden access to
programs and support a more repeatable
pipeline of opportunities.
• Partnerships and integrations are an
increasing contributor to growth.
Partner related contracts (including
eCOA and CRO) accounting for
approx. 40% of value of new sales
contracts in FY26.
13
Financial Summary - Operational Leverage Evident
Key Points:
Revenue growth:
• Expansion into new indications.
• Market expansion through partner model.
• Offering strength with growth in central rating and scale
management.
Margins:
• Intentional investment in expertise in new indications.
• Lower SW license mix (FY26 23%; FY25 25%) offset by
growth in technology-enabled offerings.
• 2H margins up significantly on 1H (EBITDA 1H26 24%;
2H26 35%).
Profit:
• Growth in Net Profit before Tax and Net Profit after Tax
reflecting disciplined operational management.
FY26 FY25 Movement
Total Revenue $60.9m $53.1m 15%
Gross Profit $35.4m $32.4m 9%
Gross Margin 58% 61% (3% pts)
Operating Costs ($17.0m) ($16.5m) 3%
EBITDA $18.3m $16.0m 15%
EBITDA Margin 30% 30% -
Net Profit (before tax) $16.1m $13.9m 16%
NPBT Margin 26% 26% -
Net Profit (after tax) $11.9m $10.1m 17%
NPAT Margin 20% 19% 1% pts
14
Building an AI-enabled operating platform for modern CNS trials
AI product enhancement, platform evolution
• AI-enabled Rater Training and AI-enabled
Central Monitoring are the first initiatives of a
broader AI-enabled platform for regulated CNS
trial workflows.
• The next phase extends AI and automation
across workflow orchestration and system
integration in trial operations to reduce manual
processes and improve delivery efficiency.
• This strengthens Cogstate’s differentiation as a
trusted technology partner with greater
scalability, stronger margins over time and
deeper pharmaceutical customer engagement.
• Two-year build-out over FY27 & FY28,
predominantly CapEx.
14
15
Capital Management Plans
Share Buyback
As Cogstate’s revenue and profits grows, we expect the share price to continue to hit all-time highs.
In this context, the share buyback will remain open, but we will be selective in utilising the buyback and seek to
exploit market mispricing and times of volatility.
Dividend
Increased to A$0.04 per share, fully franked, reflecting business confidence and growth prospects.
The payout ratio of approx. 40% of after-tax profits sits comfortably within our stated target of 20% - 50%.
Record Date of 24th August 2026 with a Payment Date of 22 September 2026.
Capital Expenditure
There is presently a generational opportunity to utilise technology to lift future gross margins.
Therefore, capital expenditure will increase over FY27 and FY28 as we build out an AI powered operating platform
that will enable Cogstate, over the medium term, to limit growth in employee numbers and therefore enable
expansion of gross margins.
16
FY27 Outlook and Investment Plan
Record Contracted Future Revenue
• $48.3 million expected to be recognised in FY27 (up 54%).
• Market conditions remain positive.
• Revenue growth expected, subject to level and timing of sales contracts executed throughout FY27.
Technology Investment
• Investing purposefully in technology and AI enabled workflows.
• Subject to the timing, value and conversion of new contract wins, management expects to maintain
FY26 annual EBITDA margins, notwithstanding increased investments and operating platform
enhancements.
Timing
• Consistent with recent years, it is expected that FY27 will demonstrate a second half bias with financial
results for the Jun-27 half year expected to be stronger than the Dec-26 half year.
17
Record FY26 performance is not the destination
It’s the foundation for the next phase of growth, supported by increasing CNS trial
activity, expanding market reach, stronger revenue visibility and technology-
enabled scalability.
• Stronger starting position - FY27 begins with a record contracted revenue base, providing greater visibility
than at any point in the Company's history.
• Multiple growth drivers - Expansion across psychiatry, sleep and rare diseases is broadening Cogstate's
opportunity set.
• Growing market reach - Strategic partnerships are increasing access to sponsors, programs and global
opportunities.
• Scaling platform- A record number of active and newly awarded trials creates a larger foundation for future
revenue growth.
• Technology-led leverage - Investments in AI, automation and platform capabilities are designed to support
scalable growth, margin expansion and new software-enabled offerings.
Share your feedback
Discover